Kamata J - Search Results

1

Synthesis and structure-activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors.

Nagao S, Yamane Y, Funasaka S, Tanaka K, Miyazaki K, Kotake Y, Kamata J, Watanabe-Miyano S, Toyama O, Ozawa Y, Mizui Y, Okamoto K, Ito D. Nagao S, et al. Among authors: kamata j. Bioorg Med Chem. 2014 Oct 1;22(19):5513-29. doi: 10.1016/j.bmc.2014.07.020. Epub 2014 Jul 30. Bioorg Med Chem. 2014. PMID: 25139751

2

Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor.

Okamoto K, Ito D, Miyazaki K, Watanabe S, Tohyama O, Yokoi A, Ozawa Y, Asano M, Kawamura T, Yamane Y, Nagao S, Funasaka S, Kamata J, Kotake Y, Aoki M, Tsukahara N, Mizui Y, Tanaka I, Sawada K. Okamoto K, et al. Among authors: kamata j. Int J Mol Med. 2012 Apr;29(4):541-9. doi: 10.3892/ijmm.2011.875. Epub 2011 Dec 29. Int J Mol Med. 2012. PMID: 22211243 Free PMC article.

3

Synthesis and evaluation of novel pyrimido-acridone, -phenoxadine, and -carbazole as topoisomerase II inhibitors.

Kamata J, Okada T, Kotake Y, Niijima J, Nakamura K, Uenaka T, Yamaguchi A, Tsukahara K, Nagasu T, Koyanagi N, Kitoh K, Yoshimatsu K, Yoshino H, Sugumi H. Kamata J, et al. Chem Pharm Bull (Tokyo). 2004 Sep;52(9):1071-81. doi: 10.1248/cpb.52.1071. Chem Pharm Bull (Tokyo). 2004. PMID: 15340192 Free article.

4

A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo.

Nakamura K, Uenaka T, Nagasu T, Sugumi H, Yamaguchi A, Kotake Y, Okada T, Kamata J, Niijima J, Taniguchi T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. Nakamura K, et al. Among authors: kamata j. Cancer Sci. 2003 Jan;94(1):119-24. doi: 10.1111/j.1349-7006.2003.tb01362.x. Cancer Sci. 2003. PMID: 12708485 Free article.

5

Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.

Nakamura K, Sugumi H, Yamaguchi A, Uenaka T, Kotake Y, Okada T, Kamata J, Niijima J, Nagasu T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. Nakamura K, et al. Among authors: kamata j. Mol Cancer Ther. 2002 Jan;1(3):169-75. Mol Cancer Ther. 2002. PMID: 12467211

6

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.

Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, Tohyama O, Semba T, Yamaguchi A, Hoshi SS, Mimura F, Haneda T, Fukuda Y, Kamata JI, Takahashi K, Matsukura M, Wakabayashi T, Asada M, Nomoto KI, Watanabe T, Dezso Z, Yoshimatsu K, Funahashi Y, Tsuruoka A. Yamamoto Y, et al. Among authors: kamata ji. Vasc Cell. 2014 Sep 6;6:18. doi: 10.1186/2045-824X-6-18. eCollection 2014. Vasc Cell. 2014. PMID: 25197551 Free PMC article.

7

Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.

Funahashi Y, Sugi NH, Semba T, Yamamoto Y, Hamaoka S, Tsukahara-Tamai N, Ozawa Y, Tsuruoka A, Nara K, Takahashi K, Okabe T, Kamata J, Owa T, Ueda N, Haneda T, Yonaga M, Yoshimatsu K, Wakabayashi T. Funahashi Y, et al. Among authors: kamata j. Cancer Res. 2002 Nov 1;62(21):6116-23. Cancer Res. 2002. PMID: 12414636

8

Thermosensitive visible-light-excited visible-/NIR-luminescent complexes with lanthanide sensitized by the π-electronic system through intramolecular H-bonding.

Ohmagari H, Marets N, Kamata J, Yoneyama M, Miyauchi T, Takahashi Y, Yamamoto Y, Ogihara Y, Saito D, Goto K, Ishii A, Kato M, Hasegawa M. Ohmagari H, et al. Among authors: kamata j. Front Chem. 2022 Dec 7;10:1047960. doi: 10.3389/fchem.2022.1047960. eCollection 2022. Front Chem. 2022. PMID: 36569958 Free PMC article.

9

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.

Haas S, Camm JA, Harald D, Steffel J, Virdone S, Pieper K, Brodmann M, Schellong S, Misselwitz F, Kayani G, Kakkar AK; GARFIELD-AF Investigators. Haas S, et al. Clin Res Cardiol. 2023 Jun;112(6):759-771. doi: 10.1007/s00392-022-02079-y. Epub 2022 Sep 12. Clin Res Cardiol. 2023. PMID: 36094573

10

Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data.

Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, Le Heuzey JY, Jansky P, Fitzmaurice DA, Cappato R, Atar D, Camm AJ, Kakkar AK; GARFIELD-AF investigators. Pope MK, et al. BMJ. 2021 Oct 27;375:e066450. doi: 10.1136/bmj-2021-066450. BMJ. 2021. PMID: 34706884 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page